Assessing mutation-clinical correlations and treatment outcomes in Vietnamese non-small cell lung cancer patients

Genetic profiling in Vietnamese NSCLC patients reveals a high prevalence of actionable driver mutations, supporting the integration of routine molecular testing into NSCLC management. <i>EGFR</i>-mutated patients derive significant benefits from TKI therapy, underscoring the importance of personalized treatment strategies. Further research is needed to investigate resistance mechanisms and refine targeted therapeutic approaches.